Article
Reliability of the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based test for epidermal growth factor receptor mutations integrated into the clinical practice for non-small cell lung cancers.
Cancer science - 1 Feb 2007
Tanaka Tomoaki, Nagai Yoshiaki, Miyazawa Hitoshi, Koyama Nobuyuki, Matsuoka Suguru, Sutani Akihisa, Huqun, Udagawa Kiyoshi, Murayama Yoshitake, Nagata Makoto, Shimizu Yoshihiko, Ikebuchi Kenji, Kanazawa Minoru, Kobayashi Kunihiko, Hagiwara Koichi
Abstract excerpt
Gefitinib is an inhibitor of the tyrosine kinase activity of epidermal growth factor receptor (EGFR). Accumulating evidence suggests that gefitinib may provide a survival benefit to EGFR mutation-positive non-small lung cancer patients. We have established a clinical test that can detect EGFR mutations from cytological specimens or paraffin-embedded tissue specimens that are contaminated by normal cells. This...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.